8-K: NewAmsterdam Pharma Announces Positive Phase 3 Data for Obicetrapib, Published in Leading Medical Journals

NewAmsterdam Pharma's obicetrapib demonstrates significant LDL-C and Lp(a) reductions in Phase 3 trials, with data published in The New England Journal of Medicine and The Lancet.

Summary

• NewAmsterdam Pharma announced additional data from its BROADWAY and TANDEM pivotal Phase 3 clinical trials.
• The data was presented at the European Atherosclerosis Society Congress (EAS) 2025 and published in The New England Journal of Medicine and The Lancet.
• Pooled data from the BROADWAY, BROOKLYN, and TANDEM trials showed a 45% median placebo-adjusted reduction in lipoprotein(a) (Lp(a)) after 12 weeks in patients with baseline levels ranging from 50-150 nmol/L.
• The BROADWAY trial achieved its primary endpoint, demonstrating a 33% reduction in LDL-C compared to placebo.
• An exploratory safety analysis of the BROADWAY trial observed a 21% relative reduction in major adverse cardiovascular events (MACE).
• The TANDEM trial showed that the fixed-dose combination of obicetrapib 10 mg and ezetimibe 10 mg achieved a 48.6% reduction in LDL-C compared to placebo.
• In the TANDEM trial, over 60% of patients achieved LDL-C reductions greater than 50% at day 84, and more than 70% achieved LDL-C levels below 55 mg/dL.
• Phase 2 trial data showed that obicetrapib combined with moderate-intensity statins lowered LDL-C by approximately 70% compared to placebo.
• A preclinical model showed that obicetrapib plus ezetimibe had a more than 20% greater effect in preventing plaque formation than either drug alone (-98% vs -78%).

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results for obicetrapib, indicating potential for significant advancement in cardiovascular disease treatment. The data is published in reputable journals, further bolstering the positive sentiment.

Positives

• Obicetrapib shows significant LDL-C reduction as both monotherapy and in combination with ezetimibe.
• The drug demonstrates a favorable safety profile comparable to placebo in clinical trials.
• Obicetrapib shows promise in reducing Lp(a), a key risk factor for cardiovascular disease.
• The drug has potential as a foundational therapy in cardiovascular disease management.
• The combination of obicetrapib and ezetimibe shows synergistic effects in preventing plaque formation in preclinical models.
• The BROADWAY trial observed a 21% relative reduction in major adverse cardiovascular events (MACE).

Risks

• The forward-looking statements are subject to risks and uncertainties, including those related to regulatory approval, commercialization, and clinical trial outcomes.
• Competition from other product candidates could impact the company's business.
• The company faces risks related to intellectual property claims and the ability to attract and retain qualified personnel.
• Global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts, could impact the company's business.

Future Outlook

The company believes obicetrapib has the potential to be an effective, once-daily, oral treatment that significantly reduces LDL-C and supports global regulatory filings.

Management Comments

• 'We are proud to share what we believe to be compelling clinical data from two comprehensive clinical trials conducted in the CVD space, now published in leading peer-reviewed journals and as late-breaking presentations at EAS 2025,' said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma.
• 'We believe the additional data presented today further supports obicetrapib as a meaningful advancement in the development of an oral medication to be used adjunctively to statins.'

Industry Context

Cardiovascular disease remains the leading cause of death globally, highlighting the need for improved therapeutic regimens despite the availability of lipid-lowering therapies.

Comparison to Industry Standards

• The document mentions that less than 1 in 4 patients with ASCVD achieve an LDL-C goal of less than 70 mg/dL and only 10% of very high risk ASCVD patients achieve the goal below 55 mg/dL.
• This highlights the unmet need that NewAmsterdam Pharma is trying to address with obicetrapib.
• Comparable companies in the lipid-lowering space include Amgen (Repatha), Sanofi/Regeneron (Praluent), and Novartis (Leqvio), which offer alternative approaches to LDL-C reduction.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients at risk of cardiovascular disease could benefit from a new treatment option.
• The company's employees may be motivated by the potential for obicetrapib to improve patient care.

Next Steps

• The results will support global regulatory filings.
• The company will continue to investigate obicetrapib in ongoing clinical trials, including the PREVAIL cardiovascular outcomes trial.

Key Dates

Keywords

Obicetrapib, LDL-C, Lipoprotein(a), Cardiovascular Disease, Ezetimibe, Statins, Clinical Trials, NewAmsterdam Pharma